DDB2 Polyclonal Antibody

Product Specifications

Background

Required for DNA repair. Binds to DDB1 to form the UV-damaged DNA-binding protein complex (the UV-DDB complex) . The UV-DDB complex may recognize UV-induced DNA damage and recruit proteins of the nucleotide excision repair pathway (the NER pathway) to initiate DNA repair. The UV-DDB complex preferentially binds to cyclobutane pyrimidine dimers (CPD), 6-4 photoproducts (6-4 PP), apurinic sites and short mismatches. Also appears to function as the substrate recognition module for the DCX (DDB1-CUL4-X-box) E3 ubiquitin-protein ligase complex DDB1-CUL4-ROC1 (also known as CUL4-DDB-ROC1 and CUL4-DDB-RBX1) . The DDB1-CUL4-ROC1 complex may ubiquitinate histone H2A, histone H3 and histone H4 at sites of UV-induced DNA damage. The ubiquitination of histones may facilitate their removal from the nucleosome and promote subsequent DNA repair. The DDB1-CUL4-ROC1 complex also ubiquitinates XPC, which may enhance DNA-binding by XPC and promote NER. Isoform D1 and isoform D2 inhibit UV-damaged DNA repair.

Synonyms

DDBB; UV-DDB2; DNA damage-binding protein 2; DDB p48 subunit; Damage-specific DNA-binding protein 2; UV-damaged DNA-binding protein 2; UV-DDB 2; DDB2

Gene ID

1643

Swiss Prot

Q92466

Cellular Locus

Nucleus

Host

Rabbit

Cross Reactivity

Mouse, Rat

Immunogen

201-300/427

Target

DDB2

Clonality

Polyclonal

Isotype

IgG

Conjugation

Unconjugated

Source

KLH conjugated synthetic peptide derived from human DDB2

Applications

WB, ELISA, IHC-P, IHC-F, IF (IHC-P), IF (IHC-F), IF (ICC)

Purification

Purified by Protein A.

Concentration

1µg/µl

Dilution

WB (1:300-5000), ELISA (1:500-1000), IHC-P (1:200-400), IHC-F (1:100-500), IF (IHC-P) (1:50-200), IF (IHC-F) (1:50-200), IF (ICC) (1:50-200)

Buffer

0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Modification

Unmodified

Storage Conditions

Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.

Specificity

This antibody may have a minor secondary cross-reactivity to TNFAIP3-interacting protein 2 due to a 63% non-sequential sequence similarity in the immunogen region.